Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 14/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 14/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 2/20 | 0.47 |
| ▸ | FNTB | P49356 | 2/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340867 | 0.88 | ITGB1 (0.58) | ITGB1ITGA4ITGB7PLA2G1BATG4B | |
| SCHEMBL6344233 | 0.79 | ITGB1 (0.59) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6343091 | 0.79 | ITGB1 (0.58) | ITGB1ITGA4ITGB7FNTAFNTB | |
| SCHEMBL6354021 | 0.72 | PLA2G1B (0.59) | PLA2G1BATG4BNPC1 | |
| SCHEMBL5700942 | 0.71 | ITGB1 (0.85) | ITGB1ITGA4 | |
| SCHEMBL6346137 | 0.71 | FNTA (0.51) | ITGB1ITGA4ITGB7FNTAFNTB | |
| SCHEMBL6354954 | 0.71 | NPC1 (0.49) | ITGB1ITGA4ITGB7NPC1RAB9A | |
| SCHEMBL17079626 | 0.71 | RAB9A (0.73) | NPC1RAB9AHTT | |
| SCHEMBL7381017 | 0.71 | PPARA (0.54) | ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL6343632 | 0.70 | ITGB1 (0.60) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053907-A1 | Cell adhesion inhibitors | BIOGEN, INC. A MASSACHUSETTS CORPORATION. | 2004-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053907-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | ITGB1 11/4885ITGA4 37/4885ITGB7 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.